{"id":483137,"date":"2025-12-31T20:14:23","date_gmt":"2025-12-31T20:14:23","guid":{"rendered":"https:\/\/www.europesays.com\/us\/483137\/"},"modified":"2025-12-31T20:14:23","modified_gmt":"2025-12-31T20:14:23","slug":"vanda-jumps-21-after-fda-approves-motion-sickness-therapy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/483137\/","title":{"rendered":"Vanda Jumps 21% After FDA Approves Motion Sickness Therapy"},"content":{"rendered":"\n<p class=\"yf-7hmkaz\">This article first appeared on <a href=\"https:\/\/www.gurufocus.com\/news\/4090963\/vanda-jumps-21-after-fda-approves-motion-sickness-therapy?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:GuruFocus;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">GuruFocus<\/a>.<\/p>\n<p class=\"yf-7hmkaz\">Vanda Pharmaceuticals (<a class=\"link \" href=\"https:\/\/finance.yahoo.com\/quote\/VNDA\" data-ylk=\"slk:NASDAQ:VNDA;elm:context_link;itc:0;sec:content-canvas\" target=\"_blank\" rel=\"noopener\">NASDAQ:VNDA<\/a>) <a href=\"https:\/\/seekingalpha.com\/news\/4536003-vanda-wins-fda-nod-lilly-partnered-drug\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:jumped;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">jumped<\/a> roughly 21% in premarket trading after the U.S. Food and Drug Administration approved its motion sickness therapy Nereus, also known as tradipitant, a drug developed in partnership with Eli Lilly (<a class=\"link \" href=\"https:\/\/finance.yahoo.com\/quote\/LLY\" data-ylk=\"slk:NYSE:LLY;elm:context_link;itc:0;sec:content-canvas\" target=\"_blank\" rel=\"noopener\">NYSE:LLY<\/a>). The approval allows the oral therapy to be marketed in the U.S. for the acute prevention of vomiting induced by motion, according to a company statement released Tuesday evening, setting the stage for a commercial launch in the coming months.<\/p>\n<p class=\"yf-7hmkaz\">The FDA&#8217;s decision was backed by data from three pivotal clinical trials, where tradipitant reduced the incidence of vomiting and showed a safety profile considered compatible with acute use. The drug is a neurokinin-1 receptor antagonist, and its approval could represent the first new pharmacologic treatment for motion sickness in more than four decades, a condition often described as a physiologic response that can also affect military readiness.<\/p>\n<p class=\"yf-7hmkaz\">Beyond motion sickness, Vanda is continuing to advance tradipitant for additional indications, including nausea and vomiting linked to GLP-1 therapies. The drug was licensed from Eli Lilly under a 2012 agreement, and the FDA approval could potentially mark a significant milestone for Vanda as it expands the clinical and commercial scope of its pipeline.<\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped roughly 21% in premarket trading after the U.S.&hellip;\n","protected":false},"author":3,"featured_media":483138,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[25996,6434,17970,210,1060,109058,218675,78742,218676,67,132,68,132336],"class_list":{"0":"post-483137","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-eli-lilly","9":"tag-food-and-drug-administration","10":"tag-gurufocus","11":"tag-health","12":"tag-medication","13":"tag-motion-sickness","14":"tag-oral-therapy","15":"tag-premarket-trading","16":"tag-receptor-antagonist","17":"tag-united-states","18":"tag-unitedstates","19":"tag-us","20":"tag-vanda-pharmaceuticals"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115816016474632602","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/483137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=483137"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/483137\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/483138"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=483137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=483137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=483137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}